ResultsIQ

ResultsIQ › Latest results › Dr. Agarwal's Health Care Limited

Dr. Agarwal's Health Care Limited Q2 FY27 results deck summary

NSE: AGARWALEYE · BSE: 544350

Results deck of 5 Nov 2026, summarised by AI from the filing.

Management targets 65 total facilities in FY27E, including 55 surgical, with 26 additions planned in H2 FY27E.

Key takeaways

  1. FY27E network Management targets 65 total facilities in FY27E, including 55 surgical, with 26 additions planned in H2 FY27E.
  2. Greenfield additions 57 greenfield facilities added in H1 FY27, more surgical facilities than in all of FY26, driving revenue growth.
  3. Margin IndAS EBITDA margin slipped to 27.9% in Q2 FY27 from 28.4% a year earlier as operating expenses grew 32.7%.

Original filing on BSE

Dr. Agarwal's Health Care Limited Q2 FY27 results

As filed: Revenue ₹655 cr (+31% year on year), EBITDA ₹176 cr (+28% year on year), PAT ₹56.9 cr (+58% year on year), EBITDA margin 26.8% (−63 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹614 cr (+26% year on year), EBITDA ₹170 cr (+32% year on year), PAT ₹55.0 cr (+45% year on year), EBITDA margin 27.8% (+126 bps). Score 80 of 100, Above trend. EBITDA margin rose 126 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +5.8% in 30 days (Nifty 500: −2.3%).
  • Q4 FY26: Revenue ₹564 cr (+23% year on year), EBITDA ₹161 cr (+22% year on year), PAT ₹50.0 cr (+16% year on year), EBITDA margin 28.6% (−7 bps). Score 59 of 100, In line with trend. EBITDA margin was flat year on year. Consolidated profit +16% but standalone -61%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −3.0% in 29 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹530 cr (+23% year on year), EBITDA ₹144 cr (+26% year on year), PAT ₹43.6 cr (+56% year on year), EBITDA margin 27.2% (+75 bps). Score 77 of 100, Above trend. EBITDA margin rose 75 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −0.2% in 30 days (Nifty 500: −3.2%).
  • Q2 FY26: Revenue ₹499 cr, EBITDA ₹137 cr, PAT ₹36.0 cr, EBITDA margin 27.5%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹499 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +2.9% in 29 days (Nifty 500: +0.4%).
  • Q1 FY26: Revenue ₹487 cr, EBITDA ₹129 cr, PAT ₹38.0 cr, EBITDA margin 26.5%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹487 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −5.3% in 30 days (Nifty 500: +2.4%).
  • Q4 FY25: Revenue ₹460 cr, EBITDA ₹132 cr, PAT ₹43.0 cr, EBITDA margin 28.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹460 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +12.7% in 30 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹431 cr, EBITDA ₹114 cr, PAT ₹28.0 cr, EBITDA margin 26.5%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹431 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Dr. Agarwal's Health Care Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.